Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of AZD4635 in Healthy Male Subjects
NCT03710434Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imaradenant in solid tumor and prostate cancer (PCa) (8 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at 120 hours and Exposure to AZD4635 at 120 hours. Started Nov 2018; status: completed.
02
Drugs
imaradenant
03
Conditions
solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03710434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710434.